| Formulary Chapter 11: Eye - Full Chapter
|
| Chapter Links... |
 Biosimilars policy statement |
| NICE NG242: Diabetic retinopathy: management and monitoring |
| NICE NG77: Cataracts in adults: management |
| NICE NG81: Glaucoma: diagnosis and management |
| NICE NG82: Age-related macular degeneration |
| Details... |
| 11.08.01 |
Tear deficiency, ocular lubricants, and astringents |
|
|
 |
Ocular lubricants under normal circumstances should be purchased OTC. |
|
Acetylcysteine (Ilube®)
|
Formulary
|
Eye drops 5%
 For treatment of filamentary keratitis only
|
|
|
Carbomer 980 eye drops
(polyacrylic acid)
|
Formulary
|
Liquid gel eye drops 0.2%
Unit dose liquid gel eye drops (preservative free) 0.2%
Preservative free preparation only to be used for those patients with documented allergies to preservatives.
|
|
|
Carmellose
|
Formulary
|
Multidose / unit dose preservative free eye drops 0.5%, 1%
Preservative free preparation only to be used for those patients with documented allergies to preservatives.
|
|
|
Ciclosporin 0.1% eye drops
|
Formulary
|
Unit dose eye drops emulsion 0.1% (Ikervis) - For adult patients
Unit dose eye drops emulsion 0.1% (Verkazia) - For children and adolescents
|
LSCMMG: Ciclosporin (Verkazia) eye drops NMR
 NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
|
Ciclosporin 0.9 mg/mL eye drops (Cequa®)
|
Formulary
|
Unit dose eye drops.
Alternative to Ikervis® (ciclosporin 1mg/ml) for patients with moderate to severe dry eye disease who have not responded to artificial tears and who are intolerant or who have had a poor response to treatment with Ikervis® and where the system allows 3 monthly review appointments.
|
|
|
Hypromellose
|
Formulary
|
Eye drops 0.3%
Preservative free eye drops 0.3%
Preservative free preparation only to be used for those patients with documented allergies to preservatives.
|
|
|
Polyvinyl Alcohol
|
Formulary
|
Eye drops 1.4%
Unit dose eye drops (preservative free) 1.4%
Preservative free preparation only to be used for those patients with documented allergies to preservatives.
|
|
|
Sodium Chloride
|
Formulary
|
Unit dose eye drops (preservative free) 0.9% Minims®
Eye drops multidose / unit dose (preservative free) 5%
Preservative free preparation only to be used for those patients with documented allergies to preservatives.
|
|
|
Sodium Hyaluronate
|
Formulary
|
Eye drops 0.2%
Eye drops (preservative free) 0.1%, 0.2%
Unit dose eye drops (preservative free) 0.1%, 0.2%
Eye drops (preservative free ) Sodium hyaluronate 0.15% and trehalose 3% (Thealoz Duo®)
Eye drops sodium hyaluronate 2% & tamarind seed polysaccharide 0.2% (Hydramed®)
Eye Drops (preservative free) Sodium hyaluronate 0.2%, carbomer 980 0.2%
Eyedrops Sodium hyaluronate 0.1%, co-enzyme Q10 0.1%, vitamin E 0.5% (VisuXL®) short term use (max 1 month).
Preservative free preparation only to be used for those patients with documented allergies to preservatives.
The most cost effective option should be used.
|
|
|
White soft paraffin / Vitamin A 250IU/g (Hylo-night®)
(formerly known as VitA-Pos®)
|
Formulary
|
Eye ointment preservative free
2nd line to Hydramed Night
|
|
|
|
|
| .... |
Key |
|
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Scottish Medicines Consortium |
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
Homecare |
|
ICB commissioned |
|
NHS England commissioned |
|
Blueteq form needed |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Green:
Appropriate for initiation and ongoing prescribing in both primary and secondary care.
Generally, little or no routine drug monitoring is required. |
|
Green (Restricted):
Appropriate for initiation and ongoing prescribing in both primary and secondary care provided:
Additional criteria specific to the medicine or device are met, or
The medicine or device is used following the failure of other therapies as defined by the relevant LSCMMG pathway.
Generally, little or no routine drug monitoring is required.
|
|
Red medicines:
Medicine is supplied by the hospital for the duration of the treatment course.
Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.
Red medicines are those where primary care prescribing is not recommended. These treatments should be initiated by specialists only and prescribing retained within secondary care. They require specialist knowledge, intensive monitoring, specific dose adjustments or further evaluation in use. If however, a primary care prescriber has particular specialist knowledge or experience of prescribing a particular drug for a particular patient it would not always be appropriate for them to expect to transfer that prescribing responsibility back to secondary care. There should be a specific reason and a specific risk agreement, protocol and service set up to support this.
Primary care prescribers may prescribe RED medicines in exceptional circumstances to patients to ensure continuity of supply while arrangements are made to obtain ongoing supplies from secondary care. |
|
Amber level 0:
Suitable for prescribing in primary care following recommendation or initiation by a specialist.
Little or no specific monitoring required.
Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care.
Brief prescribing document or information sheet may be required.
Primary care prescribers must be familiar with the drug to take on prescribing responsibility or must get the required information.
When recommending or handing over care, specialists should ask primary care prescribers to take over prescribing responsibility, and should give enough information about the indication, dose, monitoring requirements, use outside product licence and any necessary dose adjustments to allow them to confidently prescribe. |
|
Amber level 1 (with shared care):
Suitable for prescribing in primary care following recommendation or initiation by a specialist.
Minimal monitoring required.
Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care.
Full prior agreement about patient’s on-going care must be reached under the shared care agreement.
Primary care prescribers are advised not to take on prescribing of these medicines unless they have been adequately informed by letter of their responsibilities with regards monitoring, side effects and interactions and are happy to take on the prescribing responsibility. A copy of locally approved shared care guidelines should accompany this letter which outlines these responsibilities. Primary care prescribers should then tell secondary care of their intentions as soon as possible by letter so that arrangements can be made for the transfer of care. |
|
Amber level 2 (with shared care and enhanced service):
Initiated by specialist and transferred to primary care following a successful initiation period.
Significant monitoring required on an on-going basis.
Full prior agreement about patient’s on-going care must be reached under the shared care agreement.
Suitable for enhanced service.
These medicines are considered suitable for GP prescribing following specialist initiation of therapy, as per shared care document which will be sent out with the request to prescribe, with on-going communication between the primary care prescriber and specialist. Amber Level 2 medicines require significant monitoring for which an enhanced service may be suitable. (Subject to local commissioning agreements). |
|
Do not prescribe: NOT recommended for use by the NHS in Lancashire and South Cumbria.
Includes medicines that NICE has not recommended for use and terminated technology appraisals, unless there is a local need. |
|
Grey medicines:
Medicines which have not yet been reviewed or are under the review process.
GPs and specialists are recommended not to prescribe these drugs.
This category includes drugs where funding has not yet been agreed.
|
|
Refer to local guidance. |
|
|
|
